Tumour cells will be grown as monolayer at 37°C in a humidified atmosphere (5% CO2, 95% air). DMEM (ref: BE12-604F, Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (ref: 3302, Lonza) and 1% penicillin streptomycin (ref: DE-17-602F, Lonza, Verviers, Belgium). The cells are adherent to plastic flasks. For experimental use, tumour cells will be detached from the culture flask by a 5 minute treatment with trypsin-versene (ref: BE02-007E, Lonza) at 37°C, in Hanks’ medium without calcium or magnesium (ref: BE10-543F, Lonza) and neutralized by addition of complete culture medium. The cells will be counted in a hemocytometer and their viability will be assessed by 0.25% trypan blue exclusion assay.

Download the complete PDF document here : BIOMIMESYS® hydroscaffold subcutaneous implantation_20180411



Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: